PrEP and STI Testing: What to Monitor and How Often

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

PrEP and STI Testing: What to Monitor and How Often

Quick Answer: Effective PrEP use requires four-test STI screening (HIV, syphilis, gonorrhoea, chlamydia) every 3 months — at all anatomical sites of exposure (pharynx, rectum, urethra/vagina), not just a urine sample. PrEP does not protect against any STI other than HIV, and people on PrEP have higher STI incidence than the general population because they’re sexually active by self-selection. The good news: 3-monthly screening catches most STIs within their natural pre-symptomatic window, and short-course treatment is effective. This guide explains exactly what to test, where, and how to interpret results.

Why PrEP Users Need Aggressive STI Screening

PrEP cuts HIV transmission by >99% with consistent adherence. It does nothing for gonorrhoea, chlamydia, syphilis, mycoplasma genitalium, herpes, HPV, or hepatitis C. Population-level data from PrEP rollout programmes (UK PROUD, Australian EPIC-NSW, French IPERGAY) consistently show STI rates 2–4× higher in PrEP users than HIV-negative comparators — partly because PrEP users have more partners on average (they self-select), partly because PrEP-era condom use trends down, and partly because frequent screening catches more asymptomatic infections.

The honest framing is this: PrEP is part of a sexual health package. Add structured STI screening every 3 months and you have a coherent prevention strategy. Without it, you’re protected against HIV but blind to everything else.

The Four-Site, Four-Test Standard

The CDC, BHIVA (British HIV Association), and EACS (European AIDS Clinical Society) PrEP guidelines all converge on the same screening matrix.

The Four Tests

1. HIV — 4th-generation antigen/antibody combo (Ag/Ab). In some programmes a viral load (HIV RNA) is added at month 1 because PrEP slightly delays seroconversion.
2. Syphilis — treponemal (e.g. TP-Particle Agglutination, EIA) and non-treponemal (RPR or VDRL) serology. Treponemal is the screening assay; RPR titre tracks active infection.
3. Gonorrhoea — nucleic acid amplification test (NAAT). Culture only if treatment-failure or resistance concern.
4. Chlamydia — NAAT.

Gonorrhoea and chlamydia NAATs are tested by site. A urine sample only tests the urethra. Adding a pharyngeal swab and a rectal swab catches the 50–70% of infections that occur at these sites and would be missed by urine alone in MSM populations and many heterosexual women.

The Four Sites

Research spotlight: A 2020 prospective analysis of San Francisco’s PrEP clinic cohort found that 71% of gonorrhoea infections detected on routine PrEP screening were either pharyngeal or rectal only — meaning urine testing alone would have missed them entirely. Asymptomatic STI carriage is the rule, not the exception, in active sexual networks.

The 3-Month Screening Cadence

Why 3 months? Because the asymptomatic window for most bacterial STIs is approximately 2 weeks to 3 months. At a 3-monthly cadence you reliably catch new infections before they progress to PID (pelvic inflammatory disease), epididymo-orchitis, or — for syphilis — secondary or tertiary stages. Quarterly screening also matches the natural cadence of PrEP follow-up: you’d be in for HIV and renal testing anyway, so STI swabs add only a few minutes.

Standard PrEP Visit Schedule

Doxy-PEP: The Newer Layer

The 2022 DoxyPEP and DOXYVAC trials showed that taking 200 mg of doxycycline within 72 hours of condomless sex reduces gonorrhoea, chlamydia, and syphilis by 65–88% in MSM and trans women. The CDC issued formal guidance in October 2023 supporting doxy-PEP for high-risk MSM and trans women on PrEP.

Doxy-PEP doesn’t replace screening — it complements it. The dose is single 200 mg within 72 hours of sex; no more than 200 mg in 24 hours. WHO-GMP doxycycline brands like Doxycycline Capsules or Doxt-SL are widely available. The MedsBase PrEP Starter Pack bundles Tenvir-EM with doxycycline for this exact regimen.

What Doxy-PEP Doesn’t Do

• No effect on HIV (PrEP is the HIV-specific tool)
• Limited evidence in cis women — current trial data is in MSM/trans women only
• No effect on mycoplasma genitalium (and may select for resistance)
• Doesn’t replace condoms for partners where pregnancy or other STI considerations apply

Specific STIs: What to Know

Gonorrhoea

Most pharyngeal and rectal gonorrhoea is asymptomatic. Urethral gonorrhoea usually causes discharge and burning. The current first-line treatment in the US is ceftriaxone 500 mg IM single dose; in the UK and Europe ceftriaxone 1 g IM is standard. Test of cure at 14 days for pharyngeal gonorrhoea is standard practice because of rising ceftriaxone resistance.

Chlamydia

Often asymptomatic at all sites. Untreated rectal chlamydia in MSM can cause lymphogranuloma venereum (LGV) — a more aggressive strain with proctitis and lymphadenopathy. First-line treatment is doxycycline 100 mg twice daily for 7 days (or 21 days for LGV). See our doxycycline vs azithromycin guide for context on why doxycycline replaced azithromycin as first line.

Syphilis

Has staged presentations: primary (painless chancre), secondary (rash, condylomata lata, lymphadenopathy), latent (asymptomatic), tertiary (cardiovascular and neurological complications, years later). Serology can stay reactive for years even after successful treatment, which is why RPR titres matter: a fourfold drop within 6–12 months confirms cure. First-line treatment is benzathine penicillin G 2.4 million units IM.

Mycoplasma Genitalium

Increasingly recognised as a cause of NGU (non-gonococcal urethritis) and PID. NAAT testing for M. genitalium is not yet routine in PrEP clinics globally but is becoming standard. Treatment is challenging because of macrolide resistance — moxifloxacin is often required.

Hepatitis B and C

HBV serology at baseline matters because tenofovir is active against HBV — stopping PrEP in someone with chronic HBV can cause a hepatitis flare. HCV screening is recommended annually for MSM on PrEP given the rising incidence of sexually transmitted HCV in this group.

Self-Collected Specimens: When and Why

The clinical evidence is now strong: self-collected pharyngeal and rectal swabs have NAAT performance equivalent to clinician-collected swabs. Many PrEP programmes have moved to self-swab collection in the exam room for privacy and throughput. Some run remote-care models: you collect, you ship, you get results electronically. This makes the 3-month cadence much easier to maintain.

When to Get Tested Outside the Schedule

Test now (don’t wait for the next scheduled visit) if:

• New genital, anal, or oral ulcer or sore
• Penile, vaginal, or rectal discharge
• Painful urination beyond a brief UTI
• Unexplained rash, especially on palms or soles
• Fever, lymphadenopathy, sore throat 2–4 weeks after a possible exposure (acute HIV or syphilis)
• A partner notifies you of a positive test result

Frequently Asked Questions

Can I do 3-monthly STI screening at home?

Yes — most jurisdictions now have home-based NAAT options for HIV, syphilis (fingerstick antibody), gonorrhoea, and chlamydia. Self-collected throat and rectal swabs are validated. You ship the kit, get results in 3–7 days.

Do I still need condoms if I’m on PrEP and Doxy-PEP?

Condoms still meaningfully reduce STI transmission (especially syphilis and herpes) and add a layer of pregnancy prevention. PrEP + Doxy-PEP + condoms is the highest-protection combination. Many people use condoms situationally rather than always — the right level is what you can actually maintain.

What if I test positive for an STI on PrEP?

You stay on PrEP and treat the STI. There’s no interaction between standard STI treatments (ceftriaxone, doxycycline, penicillin) and PrEP. Notify partners and re-test at recommended intervals (test of cure for pharyngeal gonorrhoea; RPR titres for syphilis).

Will frequent doxycycline cause antibiotic resistance?

Doxy-PEP raises a real concern about selecting for tetracycline resistance, particularly in gonorrhoea and S. aureus. Current CDC guidance balances this against the demonstrated 65–88% reduction in three common STIs. Surveillance is ongoing. The honest position is: doxy-PEP is recommended for high-incidence populations, monitored as we go.

What’s the difference between a screening test and a confirmatory test?

Screening tests (e.g. syphilis EIA) are high-sensitivity, designed to catch every possible case. Confirmatory tests (e.g. TPPA, RPR titre) verify a true positive. A reactive screen with negative confirmation usually means a past treated infection or a biological false positive.

Where can I get the full PrEP + STI prevention bundle?

The MedsBase PrEP Starter Pack includes Tenvir-EM (HIV PrEP) plus doxycycline (Doxy-PEP) in a single bundle. Pair with quarterly 4-site NAAT screening from your local clinic or a home-test provider. See our complete PrEP buying guide for the broader context.

Medical Disclaimer: STI screening and treatment require clinical context. Self-screening kits and online medication orders are not a substitute for working with a qualified sexual health clinic — particularly for syphilis treatment (which requires injectable penicillin), positive partner notification, and treatment of complex cases. Use this article to plan your screening cadence and recognise when escalation is needed.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.